Company intelligence / Profile preview

Biokeys

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

BioKeys was a biotechnology company based in San Diego, California, that specialized in the development of small molecule immunotherapies for viral diseases and cancer. The company's core technology platform focused on Toll-like receptor 7 (TLR7) agonists, which are designed to stimulate the innate immune system to produce endogenous interferons. Its lead clinical candidate, isatoribine, was a first-in-class TLR7 agonist investigated for the treatment of chronic Hepatitis C virus (HCV) infection. In December 2004, BioKeys was acquired by Nuvo Research Inc. for approximately $10.4 million, allowing Nuvo to integrate BioKeys' proprietary immunotherapy assets into its broader drug development pipeline.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Anadys Pharmaceuticals

Beyond the preview

Go deeper on Biokeys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biokeys.

Explore the full profile